Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.50 |
| ▸ | ALPI | P09923 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | XIAP | P98170 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CPA3 | P15088 | 1/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8630182 | 0.92 | ALPI (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL9499407 | 0.92 | ALPI (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL27480744 | 0.84 | SLC7A5 (0.49) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL27480743 | 0.84 | SLC7A5 (0.49) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL10584413 | 0.83 | SLC7A5 (0.62) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL5328680 | 0.83 | ALPI (0.52) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL7418449 | 0.80 | ALPI (0.50) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL8628526 | 0.80 | ALPI (0.50) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL11569665 | 0.80 | SLC7A5 (0.54) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL9716075 | 0.78 | ALPI (0.49) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015810-A1 | INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS | APELLIS PHARMACEUTICALS, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20090220572-A1 | Injectable Combination Therapy for Eye Disorders | POTENTIA PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015810-A1 | INJECTABLE COMBINATION THERAPY FOR EYE DISORDERS | CFD, CFB, CFH | SLC7A5 1892/4885ALPI 3508/4885PKM 2616/4885 |
| US-20090220572-A1 | Injectable Combination Therapy for Eye Disorders | CFD, CFB, CFH | SLC7A5 1892/4885ALPI 3508/4885PKM 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.